Document is current
Any future updates will be listed below
-
Authors
Lalli, Giovanna https://orcid.org/0000-0002-5163-640X
Schott, Jonathan M https://orcid.org/0000-0003-2059-024X
Hardy, John https://orcid.org/0000-0002-3122-0423
De Strooper, Bart https://orcid.org/0000-0001-5455-5819
- License Information
-
More Information
Article History
Received: 28 June 2021
Accepted: 8 July 2021
First Online: 2 August 2021
Conflict of interest
: GL has no competing interests. JMS has consulted for Biogen and was a member of the EMERGE and ENGAGE Interpretation Task Force. He is Chief Medical Officer of Alzheimer’s Research UK and Medical Advisor to the UK Dementia Research Institute. Views expressed here do not necessarily reflect those of these organizations. JH is an occasional consultant for Eisai on their microglial programme and an advisor for Eli Lilly on their amyloid programme. BDS is consultant for Eisai, ReMYND NV, AbbVie and Muna‐K5. He is the scientific founder of Augustine TX and Muna‐K5 and has a small amount of shares from Muna‐K5. He is director of the UK Dementia Research Institute. The commentary reflects his personal views. BDS is a senior academic editor of EMBO Molecular Medicine .
